Evaluation of the ‘skycig’ electronic cigarette for nicotine delivery and subjective effects following acute use in regular users

Lynne Dawkins1 & Olivia Corcoran2

1Drugs and Addictive Behaviours Research Group;http://www.uel.ac.uk/psychology/research/drugs2Medicines Research Group; http://www.uel.ac.uk/mrg/index.htm

Conflict of Interest & Funding

This study was funded by SKYCIGS

Lynne Dawkins has previously undertaken research for e-cigarette companies, received products for research purposes and funding for speaking at

research conferences

Olivia Corcoran has no conflicts of interests to declare

E-cigarettes: what are they?

Previous Research:• Survey data suggest that the majority of smokers use e-

cigs to stop smoking (74%; Dawkins et al., 2013)

• Bullen et al. (2010) – Relative to 0mg, the16mg (Ruyan) e-cig reduced craving

but not withdrawal symptoms over 60 minutes.– Mean tmax: 19.6 mins; mean Cmax: 1.3ng/ml

• Eissenberg (2010)– Compared 2 brands of 16mg e-cigs to tobacco smoking– Only tobacco smoking sig raised blood nicotine levels – Both e-cigs ineffective at suppressing craving

Previous Research:

• Ineffective / inconsistent vaping in naive users?

• Vansickel & Eissenberg (2013)– Effective nicotine delivery

in 8 experienced ‘vapers’ – Increase from 2ng/ml at

baseline to 10.3ng/ml within 5 mins

– Mean tmax: 60 mins; mean Cmax: 16.3ng/ml

Plasma Nicotine

-5 5 15 30 45 60 750

5

10

15

20

25

Time (minutes)10-Puff Ad-Lib

ng/m

l

Current Aims:

• To replicate the Vansickel & Eissenberg (2013) study design in a sample of habitual e-cigarette users (vapers) using a standard cigarette-like cartomizer e-cigarette (the SKYCIG) with 18mg/ml nicotine cartridge

• To explore effects of the e-cigarette on urge to smoke, tobacco-related withdrawal symptoms and adverse effects

Methods• Participants: 14 regular SKYCIG users (3

female; mean age 37) • The E-cigarette: skycig 2-piece cartomizer

e-cigarette fitted with 18mg/ml Crown Tobacco Bold cartridge

Procedure

Overnight abstinence baseline 10 puffs 60m ad lib

vaping60m rest

(no vaping)

B = bloodQ = questionnaires

BQ

BQ

BQ

BQ

B B B

Analysis of nicotine from plasma samples conducted by ABS Labs via mass spectrometry

Questionnaires• Fagerström Test of Cigarette Dependence

(baseline)• Mood & Physical Symptoms Scale (MPSS; West &

Hajek, 2004): depressed, irritable, restless, hungry, poor concentration (all rated from 1-5) & urge to smoke (rated from 1-7).

• 21 item VAS assessing side effects – e.g.:

Not at all extremely

Nausea

Demographic & smoking/vaping related information

N Min Max Mean SDAge started smoking 14 13 20 15.6 1.9

Duration of smoking cessation (months)

8 1.5 12 5.6 3.2

Duration of skycig use (months)

14 1 17 4.7 3.8

Cartridges per day 14 1 4 1.8 0.8

Puffs per day 9 25 200 98.3 65.1

FTCD 14 0 8 4.0 2.6

CO level 14 1 5 3.2 1.4

Plasma nicotine (ng/ml) 14 0.5 1.4 0.7 0.3

Mean plasma nicotine levels

Baseline 10 mins after 10 puffs

15 mins ad lib vaping

30 mins/vaping 45 mins/vaping 60 mins/vaping 60 mins rest0

2

4

6

8

10

12

14

16

Nic

otin

e ng

/ml o

f blo

od

• Sig increase from mean of 0.7 ng/ml at baseline to 5.4 ng/ml at end of 10 puff period (p < 0.01)

• Mean max of 13.8ng/ml by end of 60 mins ad lib vaping

Error bars = 1SE

Individual nicotine levels

baselin

e

10 mins a

fter 10 puffs

15 mins a

d lib va

ping

30 mins/v

aping

45 mins/v

aping

60 mins/v

aping

60 mins r

est0

5

10

15

20

25

30

Nic

otine

ng/

ml o

f blo

od

• Mean puffs: 29• Moderate, non-sig correlation between number of puffs and plasma nicotine (r = 0.48, p = 0.16)

Withdrawal symptoms & Urge to smoke Error bars = 1SE

• Sig reduction in MPSS scores and urge to smoke from baseline to 10 puffs and 60 mins ad lib vaping (p < 0.05)

Baseline 10 puffs 60 mins/vaping 60 mins rest5

6

7

8

9

MPS

S sc

ore

Baseline 10 puffs 60 mins/vaping 60 mins rest0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

Urge

to sm

oke

scor

e

Adverse EffectsSide Effect Min Max Mean SEM

Light-headedness 4 85 41.36 7.37Throat irritation 3.5 75.5 27.25 7.53Dizzy 3.5 59 24.82 5.54Salivation 3.5 66.5 20.71 5.58Mouth irritation 4.5 62 16.54 4.75Weak 4 69 14.86 4.90Cold hands/feet 3 50 10.82 3.32Pounding heart 3 29 10.71 2.40Headache 0 56 10.61 3.81Sweaty 3.5 48.5 9.79 3.08Mean TOTAL 3.9 21 12.81 1.45

Summary/Conclusions

• Effective plasma nicotine concentrations can be achieved via use of an e-cigarette cartomizer device (skycig) in habitual users

• Wide individual variation & gender effects• The skycig seems to be effective in

alleviating urge to smoke and tobacco-related withdrawal symptoms…

• …And associated with low reporting of adverse effects

Future Directions/Implications

• Future work should explore effects of vaping topography and device characteristics in relation to nicotine delivery

• Level of nicotine in cartridges may not be important if vapers can adapt the way they vape to influence nicotine delivery

Acknowledgements:

Thanks to:• Skycigs for funding the study • ABS labs for bioanalysis of nicotine from

plasma• Paula Booth for recruitment and data

collection • Participants